Good day and welcome to the DENTSPLY International Third Quarter 2015 Earnings Call. Today’s call is being recorded. At this time, I’d like to turn it over to Mr. Derek Leckow, Vice President of Investor Relations. Sir, you may begin.

Thank you, Kayla. Good morning, everyone. Thank you for joining us to discuss DENTSPLY International’s third quarter 2015 results. I’m joined by Bret Wise, DENTSPLY’s Vice Chairman and Chief Executive Officer; Chris Clark, our President and Chief Financial Officer; and Jim Mosch, our Executive Vice President and Chief Operating Officer. I hope you had a chance to review our press release issued earlier this morning. A copy of the release and a set of supplemental slides and information relating to our non-GAAP financials are available for download in the investor relations section of our website, www.dentsply.com under the heading Quarterly Results. And of course the Safe Harbor language and U.S. GAAP reconciliation contained in today’s press release also pertain to this conference call. We may make forward-looking statements involving risks and uncertainties. These should be considered in conjunction with the risk factors and uncertainties that are described in the release and in our SEC filings. It is possible that actual results may differ materially from the forward-looking statements that we make today. The Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this call. With that, I would now like to turn the call over to Bret Wise. Bret?

Thank you, Derek. Good morning everyone. Thanks for joining us this morning on our third quarter call. I’m going to give some brief overview comments on our results and our strategies and then turn over the call to Jim and Chris for more details on both the operating objectives and the financial results. As an overview, DENTSPLY continues to execute well and consistent with our strategy in a global market that we view as stable. With what we had seen earlier in the year, this market view is generally consistent across most of the geographies, although I would add that the third quarter is always the most difficult read through on trends, particularly in Europe. For DENTSPLY specifically, we’ve been executing on our strategy to first create a significant improvement in the efficiency of our global platform and then once the program gains momentum, to use a portion of those savings to accelerate growth investments. As you’ve seen in recent quarters and I think will be evident again today, we’ve been very successful in significantly improving our margin profile and I think it’s fair to say that we’re well ahead of plan that we put forth to you early last year. In order to have us on the same base line, you’ll remember that in April 2014 or about 18 months ago, we announced the global efficiency program with an objective to increase our margin profile to 20%, our operating margin profile to 20% by2017 and that would have been a 240 basis point improvement off of the 17.6% margin we reported in 2013. The second objective of the program and perhaps the most important objective, was then to use a portion of the savings generated above this objective to reinvest in growth opportunities while still meeting or exceeding the…

Thank you, Bret. I’d like to provide an operational update for Q3 and also provide some further perspective on 2015 initiatives. I’ll then turn it over to Chris for the financial review. In looking at our Q3 sales performance, our global consumables business grew mid-single digits and we believe above market, with growth led by rest of world, solid growth in the US and also positive in Europe. Our procedural selling programs and new product launches continues to support our consumable business globally. Dental specialties grew low single digits, with growth somewhat impacted by generally slow conditions in Europe, continued price competition in the orthodontics market and contraction in CIS and the specialties. These factors were favorably offset by several new products in our endodontic business, Ortho volume growth in the US, expansion of our line of business and continued good performance with our EV Implant system introduced last year. Our lab business was down mid-single digits in the quarter, which was heavily influenced by the impact of discontinued products. We have outlined previously the global restructuring of our lab business, which includes discontinuing certain commoditized lines, selling some product lines, and or businesses and also right sizing the cost structure away from what had historically been a precious metal based market. The restructuring will be substantially completed at the end of this year. However, there will be an impact through the middle of next year as we anniversary the discontinuation of several product lines. We have now initiated all major elements of the restructuring and are confident that this will lead to improved commercial focus and profitability, driven by a streamlined portfolio and transition to higher growth and more profitable laboratory materials. As we move to Q4, we have several new product launches planned across our businesses. Our restorative…

Thank you, Jim and good morning everyone. I’d like to provide some detail on our third quarter results by reviewing key elements of our income statement, balance sheet and cash flow statement and also provide some additional color on our margin improvement initiatives. For the third quarter, sales excluding metals declined 7.7% compared to prior year as internal growth of 1.7% was more than offset by negative currency translation of 9.1%. Net acquisition growth was negative 0.3% in the quarter. That’s primarily reflecting the impact of several small divestitures of non-core product lines that more than offset the impact from acquisitions. Also as Bret mentioned, the impact of discontinued products reduced the quarter’s internal growth rate by approximately 50 basis points. We continued our very strong operating margin performance in the third quarter as our operating margin rate of 20.9% of sales, excluding precious metals on an adjusted basis, improved by 220 basis points over 18.7% in the prior year quarter. This represents the accelerating impact of our global efficiency improvement initiative, which I will provide more perspective on in a moment. For the first three quarters of 2015, our adjusted margin operating rate of 20.3% represents 170 basis points improvement, over the same period in 2014. Approximately one third of the operating margin improvement this quarter was the result of currency, which continues to be a headwind to our sales and earnings, but is a tailwind currently to our operating margin rate. Currency will become a headwind to our operating margin rate in 2016 if rates remain similar to today, but will be more than offset by savings from the efficiency program. At this point, we would expect margin expansion next year despite this. We will update you more when we report our year end results. Gross profit on…

[Operators Instructions] We’ll take our first from John Kreger with William Blair.

Good morning guys. It’s actually Robbie filing in for John today. Thanks for taking the questions. Just starting on the marketing steps, thanks for the detail and some of the onetime items that impacted growth in the quarter, but even adjusting for those, it seemed like there was a little bit of a deterioration in internal growth. Can you help us understand that? Are you seeing any packets of weakness or any particular areas where things seem to be slowing?

Robbie, I’ll take a shot at that. I think we prefaced our comments by the third quarter is probably the most difficult to evaluate trends in because we have extended vacation periods, particularly in Europe and then also the US can be affected by that as well. I think if you adjust for the discontinued products, the US probably is a little bit light this quarter. We don’t recognize -- we don’t see some overlying trends that caused that. It’s just a few of our businesses were a little bit weaker than we thought they would be. We think that’s probably timing. Europe was only up slightly in the quarter. Of course it was depressed by the CIS, although that’s diminishing. In southern Europe, we saw continued growth. In northern Europe, it was more flattish, but that’s where the impact from the discontinued products is hitting. So I don’t think there’s any material change in trends there. And in the rest of world category, we were in pretty good shape, except for this disruption we had in China because of the plant, the explosion of the plant at the port. Our plant didn’t explode, but we did lose the access to that plant and the plant was damaged. Those factors would affect the rest of world. So I don’t really -- I don’t read a lot into the trends that we saw. I think the markets are stable and we are looking now to reinvest in certain markets where we see good growth potential.

Great. And on that point, it sounds like there were a couple of things that you mentioned in terms of new product introductions stepping up next year, rep additions increasing in Q4 and Q1. Can you give us any more detail on that? Maybe just contextualize how many more new products are expected, how many reps you expect to add and then maybe when you expect to see some of these reinvestments and growth to show up on the topline. Will it be a more 2016 event or more of 2017? Thanks.

Okay, I’m going to take a stab at a couple of those questions and then ask Jim to address the new products. We gave you some insights on the number of technical people we are putting into the markets as part of the reinvestment Jim did this morning. With respect to the rep expansion, we are going to withhold that for now because that’s competitively sensitive, but it’s a meaningful addition that we’ll be going in between now and the end of the first quarter. I don’t think it will have any real effect in the fourth quarter, meaning we have to hire these people, onboard them, get them trained and get them out in the field. So I think it’s more of a 2016 impact at this point, not a 2015 impact. Jim, you have some insights on the new product questions he raised?

Yeah, absolutely Robbie. From a standpoint, obviously what we outlined is we have a couple of key launches that are happening in Q4 of this year. I mentioned the Midwest can piece and also the new Cavitron. These are equipment products. They have a higher ticket price than our general consumables and it’s always favorable that they have those launching at the end of the year and we expect some good performance from those. Obviously those products will carry going forward. In addition, as we look at next year, I think typically, ideally you’d like to have a situation where you have this constant, consistent stream of new products. The reality is, is that there is somewhat of an ebb and flow to that process. And really what we are seeing right now is, we are seeing a pretty large wave of products that will be coming out in the first quarter. I can say that those are pretty much across all of our segments. We have a couple of notable additions in our healthcare business, also within our preventive business as well. So I believe that what you’re going to see in really the first half of next year is pretty consistent new product additions across all segments.

We’ll take our next question from Jeff Johnson with Robert Baird.

Thanks guys. Good morning. Can you hear me okay? Bret, let me just start with you on the topline kind of going back to Robbie’s question. If we do the math and adjust per the China port issue and the lab divestitures, maybe organic growth 2.5%, a little north of that potentially. Probably a little bit below market at this point, although we’ll see when some of the others report here if that’s true or not. As we think about these investments and the new product flow Jim was just talking about, are those investments as we get into 2016, you think to drive the growth rate back up to market or nicely above market? Just how do we judge that and how should we scorecard you guys on that over the next few quarters?

Okay, I’ll take a shot at that, Jeff. At this point the only data point we have is one of the manufacturer that’s reported and that sounded like their growth, organic growth was about like ours for consumables. So we’ll know more of course when we have the two major dealers report and we get a couple of the other industry participants reporting. But I would guess we are close to market absence the things that were specific to us, like the discontinued products and the loss of the plant in China. The new investments, one thing I commented on in my prepared remarks was, we've been fighting this fight since the recession, meaning there hasn’t been robust organic growth which means there is not excess earnings to put into growth initiatives. You might remember when we started this efficiency initiative, one of the major themes was to get our fixed cost down to give us flexibility to put money into growth initiatives. We are at that point now more so than any other point in the period since the recession. So I'm more optimistic now than I have been for probably five or six years that as we get these excess earnings and the ability to reinvest, we’ll drive our organic growth above market. I don’t want to concede that we are below market now. I'm not sure we are. I think that the one data point we've seen thus far says we are at about market right now. But I think the key is some variable spending that will allow us to push that higher and I think that’s what you’re going to start to see as we move into 2016.

All right, that’s helpful. Thank you. And then Chris, maybe just a couple of quick P&L clarifying questions. One is, as we think about the FX headwinds to margin rate or margin percentage next year, I know you don’t want to give 2016 guidance, but can you talk just about kind of, are those going to be -- Should we be thinking about 30 to 50 basis points of headwinds from the margin, from the hedge issues or how should we think about the quantification of that?

Yeah, if you look obviously the rates are moving around a lot, so it’s going to be pretty variable. We’ll give you a more formal update when we provide the guidance on the next call. At current rates it would be basically at the higher end of that range that you indicated. And again, it’s -- At this point in time, that’s based on today’s rates and these are highly volatile.

Yeah, understood. And then my last two, just I want to make sure the equity and affiliate lines, the $10.8 million, I think all that was excluded. That’s probably a DO adjustment. I think all that was excluded in the non-GAAP EPS. Just want to confirm that. And then what drove the interest in other line down about $7 million year over year and then how did that impact or play into EPS?

There is a couple of things going on there. You’re right; the vast majority of the affiliated equity did pull out in the context of non-GAAP adjustment. That really relates to a transaction relative to DO where we redeemed the convertible bonds. We still are a minority shareholder, but the bonds were on the turn and we made the decision that it was not in our best interest at this stage to go ahead and redeem those at this point in time. Based on that, there are some mark to market elements that float through both that line as well as the interest and other. So those are the bulk of the adjustments.

And those are pulled out.

Those are removed from non-GAAP result, correct.

All right. Thank you.

We’ll take our next question from Erin Wilson with Bank of America Merrill Lynch.

Great, thanks. Can you elaborate on what you’re seeing regionally across the implant business? Have you been seeing any sort of meaningful changes in pricing or competitive dynamics just in light of the consolidation or actually as the disruption or integration processes actually helped you and how do you envision that market kind of evolving over the near and longer term?

Okay, I’ll take – Jim, you want to take a stab at it?

Yes, absolutely. Erin, I think form the standpoint of the implant market, I think we would say that it’s been fairly stable over the last couple of quarters. Obviously we haven’t seen a lot of reporting from the other implant players, so it’s a little bit difficult to gauge their results. But overall, like I said we would say that the market has been fairly stable. Obviously the US is probably stronger versus Europe. Europe has been a little bit of a mixed bag, but really hasn’t changed over the last couple of quarters. From the standpoint of the market overall, I think we would expect it to continue at its current pace. It might improve slightly next year. Competitive factors as far as pricing, average sale prices, some pressure on average sale prices, but not significant.

The thing I’d add to that is that our new system continues to get good uptake and it’s a premium system. So we are getting good conversions from that new system at the price point that we got it marketed at. So that’s a favorable data point I think.

Okay, great. And you briefly touched on this, but can you speak to just the broader underlying demand trends in the US and how we should think about the quarterly progression here?

Erin, I’d say it’s consistent with what I said before. In the US, August isn’t a really great month to gauge. I would say the quarter probably started a little bit stronger than it finished, but we are talking a few basis points here. I don’t think it’s something that I would read any material trend into. We are still getting good interest in new products that we bring to market. Our reps I think are doing a good job of maximizing those. So I think the trends are stable as we said in our prepared remarks in the US.

Okay and just one quick one. What’s embedded in your expectations as far as it relates to the discontinued products in the fourth quarter?

The fourth quarter I think is Christmas in fact.

It’s accelerating. So as we look at it, we've got -- we obviously don’t provide internal growth guidance basically. But included in our expectations for the quarter is an increasing headwind from the discontinued products.

That will be a little bit heavier in Q4 and Q1 and then by midyear next year it will start to abate.

It will begin to come back down.

Okay, great. Thank you.

We’ll take our next question from Steve Beuchaw with Morgan Stanley.

Good morning guys. Thanks for taking the questions. Just one for Bret. Bret, I’d like to open the floor up and give you a chance to talk about what it is you’re seeing in your dialogue over the last several weeks with investors as it relates to the Sirona transaction. Where you feel like you wanted to invest or needed to invest the most time to help people understand the merits of the deal, the parameters of the deal just to help people get comfortable as they think about the story.

Steve, we are in the regulatory approval process right now and the process of filing for a trust approval and also shareholder approval. I think on this point we've got to stick to the script that we had at the time we did the announcement. The two companies are still operating independently of each other at this point. And so I think I’d refer you back to the slide deck that we have from the announcement in mid-September. I don’t think we can go any further than that on this call this morning.

Okay, I had to try. Then I’ll ask just two quick clarification questions. One on trend in the quarter. Setting aside the impact of discontinued operations, did you see anything in the channel as it relates to inventory in the distribution channel that might have been impactful on the results of the quarter?

I'm going to start this and Chris if you have something to add. No. I think that we had a price increase October 1, which we do annually on October 1 and we saw kind of the same activity from the channel that we normally do. So no, I don’t think I saw any material difference.

No. Steve I guess I’d add, I think our price increase was pretty similar to the rate it’s been in prior years. Generally in that point to point and a half range. I think the behavior of our distributors was very similar to what it’s been. There are some businesses that might have been a little bit longer or shorter in the context of the pre-buy but those tend to average out. And so I’d say, overall pretty similar impact to what we've seen in the past.

Okay and then last one for me actually relates back to Tianjin. You mentioned in the prepared remarks that it was offline for five to six weeks and I believe you mentioned that that was in August. Have we seen any of that impact recapture and do you have a rough sense for the magnitude of the impact in the quarter? Sorry if I missed that in the prepared remarks. Thanks.

I don’t think we quantified that in the prepared remarks. I'm going to start this and then Chris if you want to quantify you can. The plant got back up and running and also we got availability of the inventory that was in the facility in late September. So we lost a good five weeks, maybe even six weeks, but it occurred, the explosion was in early August and by the time we exited the quarter, we had full access to the facility again. I just want to make clear that in a country like China where we import product into and we hold it in a logistics point, we don’t have the flexibility to do a rush of new products into the country because they’ve got to clear the port. So the fact that we lost access, not only the manufacturing, but to the inventory to ship, is what caused this disruption.

Yeah. I think roughly the difference in trajectory on that business alone had about a 60 basis point impact approximately on the total internal growth number and about 300 basis points on rest of world. So again, it’s hard to tell but if we look at the difference in trends, that’s the impact.

Guys, thanks again. Have a good morning.

We’ll take our next question from David Stratton with Great Lakes Review.

Good morning. I just have a housekeeping question regarding the current liability. That jumped about 40% and I just want to make sure that that is all attributable to the long term debt drop being transitioned into current portion of long term debt. Thank you.

That’s exactly right. Yeah, you got it.

All right, thanks.

I would add those liabilities will likely be refinanced.

Yes, Correct. Our intentions are to refinance these in the near term, but they did move in the quarter from long-term to current.

[Operator instructions]. We’ll take our next from Brandon Couillard with Jefferies.

Thanks. Good morning. Chris, on the working capital front, you made considerable progress of bringing down inventory. Should we expect that trend to level out as you build stocks for the new product launches coming up over the next say six to 12 months? And then could you give us a revised view on CapEx for the year?

Yeah, sure. On the inventory obviously we don’t provide guidance on a quarterly basis, but I guess I would say over a period of time, we've brought it down gradually. I would have the expectation that it continues to come down gradually. We may have an individual quarter where it may stay stable or come up a little bit based on either transitional items, transitional initiatives we have in the near term relative to the margin improvement initiatives, or quite frankly new products as you mentioned. But I guess they’d take a longer time or moderate, intermediate term view on it Brandon to say that I would expect -- we've got considerable room to continue to bring this thing down. Relative to CapEx, at this point in time our CapEx expenditures are relatively modest based on historical trends so far. I think that that is an area again relative to our asset turns that we are focusing on. And I guess I would say for the year, I would anticipate it being in the $65 million to $80 million range for the year.

Super. Thank you.

There are no further questions in queue at this time. I’d like to turn it back to our speakers for any additional or closing remarks.

Thank you all very much for your interest in DENTSPLY. That concludes our conference call. I’ll be around today for follow-ups. Thank you.